Ezabenlimab (BI 754091) Plus Modified Docetaxel, Cisplatin, and 5-Fluorouracil (mdcf) Followed by Chemoradiotherapy (CRT) in Patients (pts) with Stage III Squamous Cell Anal Carcinoma (SCCA): Early Efficacy Endpoint Results from the Phase II INTERACT-ION Study.